Clinical trials: Asthma Patients
Asthma in Children
Evaluation of the Asthma Management Program to Promote Activity for Students in Schools (Asthma-PASS)
Physical activity (PA) is an important component of asthma management in children. Studies show that PA is associated with decreased severity of asthma symptoms, as well as improved disease control and quality of life.
- Trial name
- NCT04576442
- Testing
- Asthma-PASS, Basic Asthma Management (AM), Child/Caregiver Education session
- Where
- United States
- Volunteers
- 452 people
- Sponsor
- Montefiore Medical Center
Asthma
Feasibility and Acceptability of the Propeller Monitoring System in Children With Persistent Asthma
The main hypothesis of this study is to see if children and adolescents with poorly controlled asthma will find the Propeller electronic monitoring device is feasible and acceptable, and will result in improved medication…
- Trial name
- NCT03648450
- Testing
- Propeller EMD
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Connecticut Children's Medical Center
Asthma
Efficacy and Safety Study of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.
This study aimed to determine the efficacy and safety of QAW039 150 mg and QAW039 450 mg, compared with placebo, when added to GINA (Global Initiative for Asthma) steps 4 and 5 standard-of- care (SoC) asthma therapy (GINA 2016)…
- Trial name
- NCT02555683
- Testing
- QAW039
- Where
- 234 sites in United States, Argentina and 25 more
- Volunteers
- 894 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants ≥ 18 Years of Age With Asthma
The goal of this study is to assess and compare the safety and tolerability of salbutamol administered via metered dose inhaler (MDI) containing propellant 1,1-difluoroethane (HFA-152a) or 1,1,1,2-tetrafluoroethane (HFA-134a) in…
- Trial name
- NCT06261957
- Testing
- Salbutamol HFA-134a, Salbutamol HFA-152a
- Where
- 102 sites in United States, Argentina and 11 more
- Volunteers
- 471 people
- Sponsor
- GlaxoSmithKline
Asthma
Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma
The goal of this study is to assess and compare the effectiveness of fluticasone furoate/umeclidinium bromide/vilanterol trifenatate (FF/UMEC/VI) with inhaled corticosteroids/long-acting beta-2 agonists (ICS/LABA) in adult…
- Trial name
- PERFORM (NCT06372496)
- Testing
- Fluticasone furoate/umeclidinium bromide/vilanterol trifenatate, Inhaled corticosteroids/long-acting beta-2 agonists
- Where
- 117 sites in United States, Argentina and 6 more
- Volunteers
- 1,358 people
- Sponsor
- GlaxoSmithKline
Asthma, Asthma Chronic
Study to Compare the Effects of Z7200 And Symbicort® Turbohaler on Respiratory Imaging Parameters in Asthmatic Patients
Primary objective: The primary objective of this study is to evaluate the effect of the products under investigation on functional respiratory imaging parameters and evaluate the particle deposition with Computational fluid…
- Conditions
- Asthma, Asthma Chronic, Asthma Bronchial, Asthmatic
- Trial name
- NCT02227394
- Testing
- Z7200, Symbicort® Turbohaler®
- Where
- Belgium
- Volunteers
- 20 people
- Sponsor
- Zambon SpA
Asthma, Chronic Obstructive Pulmonary Disease
Study of ARO-MUC5AC in Healthy Subjects and Patients With Muco-Obstructive Lung Disease
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of ARO-MUC5AC in normal healthy volunteers (NHVs), patients with moderate-to-severe asthma and patients with moderate-to-severe chronic…
- Trial name
- NCT05292950
- Testing
- ARO-MUC5AC
- Where
- 13 sites in Australia, New Zealand and 5 more
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Arrowhead Pharmaceuticals
CHRONIC OBSTRUCTIVE PULMONARY DISEASE, ASTHMA
Inhaler Lung Deposition in Chronic Obstructive Pulmonary Disease (COPD)
Patients with chronic obstructive pulmonary disease (COPD) experience breathing difficulties because the airways deep in their lungs become narrowed. COPD patients use inhaler drugs to provide relief from breathlessness.
- Conditions
- CHRONIC OBSTRUCTIVE PULMONARY DISEASE, ASTHMA, HEALTHY SUBJECTS
- Trial name
- NCT01721291
- Testing
- SALBUTAMOL
- Where
- United Kingdom
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Asthma, Genotype
Evaluate Pharmacokinetics and Safety of Slow Release DHEA
This is a study to look at pharmacokinetic levels of different doses of slow release DHEA in subjects with asthma.
- Trial name
- DHEA (NCT05623059)
- Testing
- Slow Release DHEA
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Indiana University
Asthma
A Study Evaluating the Effect of Inhaled PT007(AS MDI) Versus Placebo MDI and Ventolin Evohaler on Lung Function in Adult Participants With Asthma
Phase II study, to investigate the therapeutic efficacy and safety of inhaled PT007 (referred to as AS MDI) compared with placebo MDI and open-label Ventolin Evohaler in male and female participants aged 18 to 65 years…
- Trial name
- MITCHELL (NCT06644924)
- Testing
- Intervention: AS MDI, Intervention: Ventolin Evohaler
- Where
- 22 sites in United States
- Volunteers
- 118 people
- Sponsor
- AstraZeneca
Asthma
A Study to Assess the Potential for Airway Sensitivity Reactions With Propellants HFA-152a (Test) and HFA-134a (Reference) Administered Via Pressurized Inhalers in Adults With Mild Asthma
The purpose of the study is to assess the propellants,1 - Difluoroethane [HFA-152a] (Test) and 1,1,1,2-Tetrafluoroethane [HFA-134a] (Reference) for their potential to cause the airways to tighten when delivered through…
- Trial name
- NCT06702462
- Testing
- HFA-152A propellant, HFA-134A propellant
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- GlaxoSmithKline
Asthma
Foster 100/6 mg NEXThaler Versus Foster 100/6mg Pressurized Metered-dose Inhaler (pMDI) in Patients With Controlled Asthma.
Primary Objective To demonstrate the non-inferiority of Foster® NEXThaler® 100/6 µg versus (vs.) Foster® pressurised metered dose inhaler (pMDI) 100/6 µg in terms of pulmonary function (change from baseline to the entire…
- Trial name
- FORTUNE (NCT03453112)
- Testing
- Foster 100/6µg NEXThaler, Foster 100/6µg pMDI
- Where
- 51 sites in China
- Volunteers
- 494 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
COPD, Asthma
LungVITamin D and OmegA-3 Trial (lungVITAL)
The VITamin D and OmegA-3 TriaL (VITAL; NCT 01169259) is an ongoing randomized clinical trial in 25,871 U.S. men and women investigating whether taking daily dietary supplements of vitamin D3 (2000 IU) or omega-3 fatty acids…
- Conditions
- COPD, Asthma, Pulmonary Function, Pneumonia
- Trial name
- lungVITAL (NCT01728571)
- Testing
- Vitamin D3, fish oil
- Where
- United States
- Volunteers
- 25,871 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
Asthma in Children
A Study of Remote Asthma Management Using an Integrated Artificial Intelligence-assisted EHR Dashboard and Mobile Device Compared With Usual Asthma Care to Treat 6-17 Year Old Patients
The main purpose of this study is to look at whether clinicians and their patients with asthma can satisfactorily perform remote asthma management at home (not visiting clinic) by using an artificial intelligence tool called…
- Trial name
- NCT06062433
- Testing
- AsthmaTuner, Asthma-Guidance and Prediction System
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Pediatric Asthma
Developing a Childhood Asthma Risk Passive Digital Marker
Underdiagnosis and undertreatment is a major problem in childhood asthma management, especially in preschool-aged children. Current prognostic approaches using risk-score based tools have poor-to-modest accuracy, are impractical…
- Trial name
- NCT05826561
- Testing
- Childhood Asthma Passive Digital Marker
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Indiana University
Asthma
A Study Testing the Superiority of CHF 1535 pMDI 800/24µg Total Daily Dose Compared With CHF 718 pMDI 800µg Total Daily Dose in Adults With Asthma on Medium or High-Dose Inhaled Corticosteroid
Compare the superiority of CHF 1535 versus CHF 718 in subjects with asthma who are on medium or high dose inhaled corticosteroids.
- Trial name
- FORCE2 (NCT05292586)
- Testing
- Beclomethasone Dipropionate/Formoterol Fumarate, Beclomethasone Dipropionate
- Where
- 91 sites in United States
- Volunteers
- 1,377 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma
A Study of Lebrikizumab in Participants With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication
This randomized, multicenter, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy and safety of lebrikizumab in participants with asthma whose disease remains uncontrolled despite daily treatment…
- Trial name
- NCT01867125
- Testing
- Lebrikizumab
- Where
- 181 sites in United States, Argentina and 24 more
- Volunteers
- 1,081 people
- Sponsor
- Hoffmann-La Roche
Asthma
A Study Evaluating the Efficacy and Safety of Lebrikizumab in Adult Patients With Mild to Moderate Asthma
This Phase III, randomized, double-blind, placebo-controlled, multicenter study will assess the efficacy and safety of lebrikizumab in adult patients with mild to moderate asthma treated with short-acting beta-agonist (SABA)…
- Trial name
- NCT02104674
- Testing
- Lebrikizumab, Montelukast
- Where
- 82 sites in United States, Brazil and 9 more
- Volunteers
- 313 people
- Sponsor
- Hoffmann-La Roche
Asthma
Effectiveness and Safety Study of Tezepelumab in Adults & Adolescent Participants With Severe Asthma in the United States
To asses effectiveness and safety of tezepelumab in adult and adolescent participants with severe asthma including several under-studied populations in the United States.
- Trial name
- PASSAGE (NCT05329194)
- Testing
- Tezepelumab
- Where
- 37 sites in United States
- Volunteers
- 286 people
- Sponsor
- AstraZeneca
Asthma
Administration of ARS-1 or Albuterol in Subjects With Persistent Asthma
ARS-1 is being developed for patients as a needleless alternative route of epinephrine administration for the management of refractory asthma symptoms.
- Trial name
- NCT05363670
- Testing
- ARS-1 1 mg, Albuterol MDI, ARS-1 2mg
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- ARS Pharmaceuticals, Inc.